Jacobs Levy Equity Management, Inc Avrobio, Inc. Transaction History

Jacobs Levy Equity Management, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.29 - $4.04 $172,147 - $539,129	-133,448 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$3.45 - $6.05 $506,422 - $888,073	-146,789 Reduced 52.38%	133,448 $514,000
Q3 2021 Nov 15, 2021	SELL	$5.53 - $9.28 $346,454 - $581,392	-62,650 Reduced 18.27%	280,237 $1.56 Million
Q2 2021 Aug 16, 2021	SELL	$7.84 - $12.6 $6,640 - $10,672	-847 Reduced 0.25%	342,887 $3.05 Million
Q1 2021 May 17, 2021	BUY	$10.54 - $19.3 $2.98 Million - $5.46 Million	282,943 Added 465.44%	343,734 $4.36 Million
Q4 2020 Feb 16, 2021	BUY	$12.79 - $17.1 $777,516 - $1.04 Million	60,791 New	60,791 $847,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.